Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Down 29.6% in December

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,570,000 shares, a drop of 29.6% from the November 30th total of 2,230,000 shares. Based on an average daily trading volume, of 8,330,000 shares, the short-interest ratio is presently 0.2 days. Approximately 9.0% of the company’s stock are sold short.

Insider Activity

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.26% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals in the third quarter worth about $34,000. Certuity LLC purchased a new stake in shares of Syros Pharmaceuticals during the second quarter worth $109,000. Acadian Asset Management LLC boosted its holdings in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after acquiring an additional 17,416 shares during the period. Finally, Exome Asset Management LLC grew its position in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares in the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Stock Performance

Shares of NASDAQ SYRS traded down $0.01 during mid-day trading on Friday, reaching $0.21. 5,146,148 shares of the company’s stock were exchanged, compared to its average volume of 2,356,837. The firm has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $2.70. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. The firm has a market capitalization of $5.61 million, a price-to-earnings ratio of -0.07 and a beta of 1.33. Syros Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the business posted ($1.35) earnings per share. Analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SYRS shares. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, December 23rd. They issued a “sell” rating for the company. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Syros Pharmaceuticals currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.